Concerning the cAMP second messenger pathway and its regulation, all of the following are true EXCEPT:

Explanation

## The cAMP Signaling Pathway: Synthesis, Regulation, and Mechanism ### Correct Statements (Options 0, 1, 2) **Option 0 — Bidirectional Control of Adenylyl Cyclase:** **Key Point:** Adenylyl cyclase is regulated by heterotrimeric G proteins: - **Gαs-GTP** (stimulatory) → activates adenylyl cyclase → ↑ cAMP - **Gαi-GTP** (inhibitory) → inhibits adenylyl cyclase → ↓ cAMP This allows simultaneous stimulatory and inhibitory signals to converge on cAMP levels, providing fine-tuned regulation. **Option 1 — Phosphodiesterase and cAMP Degradation:** **High-Yield:** Phosphodiesterase (PDE) is the primary mechanism for terminating cAMP signaling: - PDE catalyzes: cAMP → AMP (not adenosine; AMP is the product) - PDE inhibitors (e.g., theophylline, milrinone, sildenafil) increase cAMP levels and prolong the signal - This is clinically exploited in heart failure (milrinone) and erectile dysfunction (sildenafil) **Option 2 — PKA Activation by cAMP:** **Key Point:** cAMP activates protein kinase A (PKA) via a well-characterized mechanism: 1. PKA exists as an inactive holoenzyme: R₂C₂ (two regulatory + two catalytic subunits) 2. cAMP binds cooperatively to the regulatory (R) subunits 3. This causes dissociation: R₂(cAMP)₄ + 2C (active) 4. Free catalytic subunits phosphorylate downstream targets (glycogen phosphorylase kinase, phosphofructokinase-2, CREB, etc.) ### Incorrect Statement (Option 3) — The Correct Answer **Warning:** Option 3 contains a **false absolute claim**. The statement "cAMP is the **only** second messenger capable of activating protein kinase A in mammalian cells" is **incorrect**. **Clinical Pearl:** While cAMP is the **primary and canonical** activator of PKA, it is **not the only** second messenger that can activate PKA: 1. **cGMP (cyclic guanosine monophosphate)** can also bind to and activate PKA, though with lower affinity than cAMP 2. cGMP is generated by soluble guanylyl cyclase (in response to nitric oxide) and membrane-bound guanylyl cyclase (in response to natriuretic peptides) 3. In certain tissues (e.g., vascular smooth muscle), cGMP-mediated PKA activation contributes to vasodilation 4. The regulatory subunits of PKA have **two cAMP-binding domains** (CBD-A and CBD-B) that can bind both cAMP and cGMP, though with different affinities **Mnemonic:** **cAMP ≠ only PKA activator**. cGMP can also activate PKA, though less efficiently. The key distinction is that cAMP is the **physiologically dominant** activator in most tissues. ### Comparison Table: cAMP vs. cGMP as PKA Activators | Feature | cAMP | cGMP | | --- | --- | --- | | **Primary source** | Adenylyl cyclase (Gαs-coupled) | Guanylyl cyclase (NO, ANP) | | **PKA activation** | High affinity; primary mechanism | Lower affinity; secondary mechanism | | **Physiological role** | Glycogenolysis, lipolysis, cardiac contractility | Vasodilation, smooth muscle relaxation | | **Tissue distribution** | Ubiquitous | Vascular, GI, neural tissues | | **Degradation** | PDE3, PDE4 | PDE5, PDE6, PDE9 | **High-Yield:** The statement "only" in Option 3 is the trap. While cAMP is the **predominant** activator of PKA, cGMP is a documented alternative ligand for the PKA regulatory subunits, especially in tissues where NO/cGMP signaling is prominent.